Urologic Oncology: Seminars and Original Investigations Urologic Oncology: Seminars and Original Investigations RSS feedThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Null association between androgen-deprivation therapy and nonprostate cancer mortality among older men with nonmetastatic prostate cancer
Androgen-deprivation therapy (ADT) has been associated with cardiovascular risk factors and the development of cardiovascular disease in men with metastatic prostate cancer. We sought to examine the effect of ADT on nonprostate cancer mortality among patients with nonmetastatic prostate cancer. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - March 1, 2018 Category: Urology & Nephrology Authors: Christopher J.D. Wallis, Raj Satkunasivam, Sender Herschorn, Calvin Law, Arun Seth, Ronald T. Kodama, Girish S. Kulkarni, Robert K. Nam Tags: Original article Source Type: research

Cover 2: Masthead
(Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - February 28, 2018 Category: Urology & Nephrology Source Type: research

Editorial Board
(Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - February 28, 2018 Category: Urology & Nephrology Source Type: research

Table of Contents
(Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - February 28, 2018 Category: Urology & Nephrology Source Type: research

Cost and cost-effectiveness studies in urologic oncology using large administrative databases
This study aimed to review the use of CEAs and other cost analyses in urologic oncology using large databases to better understand the value of management strategies of these cancers. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - February 28, 2018 Category: Urology & Nephrology Authors: Ye Wang, Matthew Mossanen, Steven L. Chang Tags: Seminars article Source Type: research

Pharmacokinetics and pharmacodynamics of intravesical and intravenous TMX-101 and TMX-202 in a F344 rat model
To evaluate and compare the pharmacokinetic and pharmacodynamic properties of 2 investigational Toll-like receptor 7 agonists, TMX-101, and TMX-202 after intravenous and intravesical administration in a rat model. TLR-7 agonists are successfully used as topical treatment for various (pre)malignant skin lesions and are now under investigation as intravesical therapy for non –muscle-invasive bladder cancer. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - February 27, 2018 Category: Urology & Nephrology Authors: Johannes Falke, Christina A. Hulsbergen-van de Kaa, Roberto Maj, Egbert Oosterwijk, Johannes Alfred Witjes Tags: Original Article Source Type: research

Recommendations for follow-up of muscle-invasive bladder cancer patients: A consensus by the international bladder cancer network
Several guidelines exist that address treatment of patients with nonmetastatic muscle-invasive bladder cancer (MIBC). However, most only briefly mention follow-up strategies for patients and hence the treating physician is often left to infer on what the preferred follow-up schema would be for an individual patient. Herein, we aim to synthesize recommendations for follow-up of patients with MIBC for easy reference. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - February 26, 2018 Category: Urology & Nephrology Authors: Tahlita C.M. Zuiverloon, Kim E.M. van Kessel, Trinity J. Bivalacqua, Joost L. Boormans, Thorsten H. Ecke, Petros D. Grivas, Anne E. Kiltie, Fredrik Liedberg, Andrea Necchi, Bas W. van Rhijn, Florian Roghmann, Marta Sanchez-Carbayo, Bernd J. Schmitz-Dr äg Tags: Seminars article Source Type: research

Novel biomarkers in bladder cancer
A sea change has occurred in the treatment options available for metastatic urothelial bladder cancer with the recent Food and Drug Administration approval of 5 immune checkpoint blockade agents for patients who have progressed on platinum-based chemotherapy or are not candidates for cisplatin. Additionally, comprehensive characterization of the landscape of genomic alterations in this disease through The Cancer Genome Atlas and other efforts has detected numerous potential targets for small molecule inhibitors. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - February 19, 2018 Category: Urology & Nephrology Authors: Michael L. Cheng, Gopa Iyer Tags: Seminars article Source Type: research

Introduction to a Seminar on implementation and de-implementation to improve urologic cancer care
This Seminar highlights real-world efforts to improve urologic oncology practice through implementation science and its methods. The essays are crafted by former fellows of the Mentored Training for Dissemination and Implementation Research in Cancer (MT-DIRC) Program sponsored by the National Cancer Institute (1 R25 CA171994-01A1), its Cancer Research Network, and the Veterans Health Administration. The 2-year fellowship program focused on capacity-building in dissemination and implementation (D&I) research to enable fellows to: (1) conduct high-quality D&I research, (2) speed up the translation of cancer prevention and c...
Source: Urologic Oncology: Seminars and Original Investigations - February 15, 2018 Category: Urology & Nephrology Authors: Ted A. Skolarus Tags: Seminars Article Source Type: research

The effect of treatment at minority-serving hospitals on outcomes for bladder cancer
Healthcare for racial minorities is densely concentrated at a small subset of hospitals in the United States. Understanding long-term outcomes at these minority-serving hospitals is highly relevant to elucidating the sources of racial disparities in cancer care. We investigated the effect of treatment at a minority-serving hospital on overall survival and receipt of definitive treatment for bladder cancer. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - February 14, 2018 Category: Urology & Nephrology Authors: Sean A. Fletcher, Philipp Gild, Alexander P. Cole, Malte W. Vetterlein, Adam S. Kibel, Toni K. Choueiri, Guru P. Sonpavde, Mark A. Preston, Daniel Pucheril, Mani Menon, Maxine Sun, Stuart R. Lipsitz, Quoc-Dien Trinh Tags: Original article Source Type: research

Understanding how prostate cancer patients value the current treatment options for metastatic castration resistant prostate cancer
Several new compounds are now available for castration resistant prostate cancer (CRPC). Individual costs range between $40,000 and $93,000 with mean survival extensions from 2.4 to 4.8 months. Currently, it remains unclear how patients with prostate cancer (PCa) value the effect of these therapies in the setting of CRPC. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - February 14, 2018 Category: Urology & Nephrology Authors: Tarik Benidir, Karen Hersey, Antonio Finelli, Rob Hamilton, Anthony M. Joshua, Girish Kulkarni, Alexandre Zlotta, Neil Fleshner Tags: Original article Source Type: research